JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy
Authors:
- 30 November 2018
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2018 (1) , 110-117
Abstract
Now that the spectrum of somatic mutations that initiate, propagate, and drive the progression of myeloproliferative neoplasms (MPNs) has largely been defined, recent efforts have focused on integrating this information into clinical decision making. In this regard, the greatest progress has been made in myelofibrosis, in which high-molecular-risk mutations have been identified and incorporated into prognostic models to help guide treatment decisions. In this chapter, we focus on advances in 4 main areas: (1) What are the MPN phenotypic driver mutations? (2) What constitutes high molecular risk in MPN (focusing on ASXL1)? (3) How do we risk-stratify patients with MPN? And (4) What is the significance of molecular genetics for MPN treatment? Although substantial progress has been made, we still have an incomplete understanding of the molecular basis for phenotypic diversity in MPN, and few rationally designed therapeutic approaches to target high-risk mutations are available. Ongoing research efforts in these areas are critical to understanding the biological consequences of genetic heterogeneity in MPN and to improving outcomes for patients.Keywords
This publication has 66 references indexed in Scilit:
- Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapyBlood Advances, 2017
- Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosisBlood, 2017
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia, 2016
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationHaematologica, 2016
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasmsLeukemia, 2015
- Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosisBritish Journal of Haematology, 2015
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patientsLeukemia, 2014
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- RECOMBINANT INTERFERON-ALPHA FOR TREATMENT OF POLYCYTHAEMIA VERAThe Lancet, 1988